Clinical Course and Outcomes of Single-Organism Enterococcus Peritonitis in Peritoneal Dialysis Patients
| Autor: | Sydney C.W. Tang, Man Fai Lam, Terence Yip, Ivan Hung, Kai Chung Tse, Wai Kei Lo, Sing L. Lui, Flora S.K. Ng, Kar N. Lai, Tak Mao Chan |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Antibiotics Peritonitis Staphylococcal infections Gastroenterology Peritoneal dialysis Vancomycin Internal medicine medicine Humans Escherichia coli Infections Gram-Positive Bacterial Infections Aged Retrospective Studies Aged 80 and over biology business.industry Hazard ratio General Medicine Middle Aged Staphylococcal Infections medicine.disease biology.organism_classification Abdominal Pain Anti-Bacterial Agents Surgery Logistic Models Treatment Outcome Enterococcus Nephrology Female Complication business Peritoneal Dialysis medicine.drug |
| Zdroj: | Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 31:522-528 |
| ISSN: | 1718-4304 0896-8608 |
| Popis: | Background and Objectives Enterococci are part of the normal flora of the gastrointestinal tract. They can cause enteric peritonitis, which is a serious complication of peritoneal dialysis (PD). However, the clinical course and outcome of PD-related Enterococcus peritonitis remains unclear. Methods We reviewed all Enterococcus peritonitis episodes occurring in our dialysis unit from 1995 to 2009. Results During the study period, 1421 episodes of peritonitis were recorded. Of 29 episodes (2.0%) that were attributable to single-organism Enterococcus, 12 episodes were caused by E. faecalis; 9, by E. faecium; and the remaining 8, by other Enterococcus species. The overall rate of ampicillin resistance was 41.4%. Recent use of antibiotics was associated with the development of ampicillin-resistant Enterococcus (ARE) peritonitis (hazard ratio: 12.53; p = 0.04). The primary response rate of Enterococcus peritonitis was significantly higher than that of Escherichia coli peritonitis (89.7% vs. 69.9%, p = 0.038), but the primary response rate was not significantly lower for ARE peritonitis than for ampicillin-susceptible Enterococcus (ASE) peritonitis (83.3% vs. 94.1%, p = 0.553). However, significantly more patients with ARE had received vancomycin (83.3% vs. 23.5%, p = 0.003), with a longer mean duration of vancomycin treatment (11.8 ± 6.9 days vs. 3.7 ± 6.8 days, p = 0.005). Conclusions Recent use of antibiotics was a risk factor for the development of ARE peritonitis. Outcomes in ASE and ARE peritonitis were similar, but vancomycin was required during treatment for ARE peritonitis, in turn possibly predisposing the patients to infections caused by vancomycin-resistant organisms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|